Leading cancer research centers reinforce importance of safe and effective HPV vaccination to prevent cancer
Today, Âé¶¹Ó³» MD Anderson Cancer Center, along with 61 National Cancer Institute (NCI)-Designated Cancer Centers, leading national organizations and the University of Puerto Rico Comprehensive...
MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies
MD Anderson and TOPPAN Holdings announce strategic alliance to co-develop organoid technology for evaluating cancer treatments
UT MD Anderson and Texas Children’s Hospital announce $150 million gift from Kinder Foundation to launch Kinder Children’s Cancer Center
Âé¶¹Ó³» MD Anderson Cancer Center and Texas Children’s Hospital today announced a $150 million gift from Kinder Foundation. The transformational gift creates Kinder Children’s Cancer Center, a joint venture of UT MD Anderson and Texas Children’s, with a single mission: to end childhood cancer.
The gift is one of the largest philanthropic donations made to an American pediatric hospital and one of...
MD Anderson and UT Austin launch joint initiative to advance breakthroughs in cancer research
Âé¶¹Ó³» MD Anderson Cancer Center and Âé¶¹Ó³» at Austin have launched a joint initiative, the Collaborative...
UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer
Âé¶¹Ó³» MD Anderson Cancer Center and Texas Children’s Hospital have announced a transformational collaboration dedicated...
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
Âé¶¹Ó³» MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the...
MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award for seminal contributions to lung cancer research
Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at Âé¶¹Ó³» MD Anderson Cancer Center...
MD Anderson and AmMax Bio announce agreements to advance development of AMB-066 in colorectal cancer patients with minimal residual disease
Âé¶¹Ó³» MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical...
MD Anderson statement on BCBS TX ending Medicare Advantage and Medicaid plans
Blue Cross Blue Shield notified Âé¶¹Ó³» MD Anderson Cancer Center it will end its Letter of Agreement for Medicare Advantage...